|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: CCDC92 |
Gene summary for CCDC92 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | CCDC92 | Gene ID | 80212 |
| Gene name | coiled-coil domain containing 92 | |
| Gene Alias | CCDC92 | |
| Cytomap | 12q24.31 | |
| Gene Type | protein-coding | GO ID | GO:0005575 | UniProtAcc | Q53HC0 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 80212 | CCDC92 | HCC1_Meng | Human | Liver | HCC | 4.90e-16 | -3.78e-02 | 0.0246 |
| 80212 | CCDC92 | HCC2_Meng | Human | Liver | HCC | 1.16e-09 | 1.50e-02 | 0.0107 |
| 80212 | CCDC92 | HCC1 | Human | Liver | HCC | 1.26e-08 | 3.65e+00 | 0.5336 |
| 80212 | CCDC92 | S014 | Human | Liver | HCC | 2.56e-02 | 2.84e-01 | 0.2254 |
| 80212 | CCDC92 | S015 | Human | Liver | HCC | 4.58e-03 | 2.69e-01 | 0.2375 |
| 80212 | CCDC92 | S016 | Human | Liver | HCC | 2.09e-02 | 2.68e-01 | 0.2243 |
| 80212 | CCDC92 | S027 | Human | Liver | HCC | 6.89e-07 | 6.43e-01 | 0.2446 |
| 80212 | CCDC92 | S028 | Human | Liver | HCC | 4.36e-10 | 5.91e-01 | 0.2503 |
| 80212 | CCDC92 | S029 | Human | Liver | HCC | 2.05e-09 | 5.21e-01 | 0.2581 |
| 80212 | CCDC92 | C04 | Human | Oral cavity | OSCC | 1.09e-10 | 4.69e-01 | 0.2633 |
| 80212 | CCDC92 | C21 | Human | Oral cavity | OSCC | 4.80e-11 | 3.83e-01 | 0.2678 |
| 80212 | CCDC92 | C30 | Human | Oral cavity | OSCC | 1.39e-29 | 1.04e+00 | 0.3055 |
| 80212 | CCDC92 | C43 | Human | Oral cavity | OSCC | 1.62e-02 | 5.54e-02 | 0.1704 |
| 80212 | CCDC92 | C51 | Human | Oral cavity | OSCC | 2.20e-04 | 3.70e-01 | 0.2674 |
| 80212 | CCDC92 | C06 | Human | Oral cavity | OSCC | 3.12e-03 | 6.50e-01 | 0.2699 |
| 80212 | CCDC92 | C08 | Human | Oral cavity | OSCC | 9.01e-04 | 1.65e-01 | 0.1919 |
| 80212 | CCDC92 | LP17 | Human | Oral cavity | LP | 6.53e-03 | 3.91e-01 | 0.2349 |
| 80212 | CCDC92 | SYSMH1 | Human | Oral cavity | OSCC | 5.33e-04 | 1.76e-01 | 0.1127 |
| 80212 | CCDC92 | SYSMH2 | Human | Oral cavity | OSCC | 1.11e-06 | 1.90e-01 | 0.2326 |
| 80212 | CCDC92 | SYSMH5 | Human | Oral cavity | OSCC | 1.94e-03 | 1.68e-01 | 0.0647 |
| Page: 1 2 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| CCDC92 | SNV | Missense_Mutation | c.892N>T | p.Ala298Ser | p.A298S | Q53HC0 | protein_coding | tolerated_low_confidence(0.33) | benign(0.059) | TCGA-D8-A1JK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| CCDC92 | SNV | Missense_Mutation | c.50G>A | p.Ser17Asn | p.S17N | Q53HC0 | protein_coding | deleterious(0.01) | benign(0.001) | TCGA-D8-A1XQ-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| CCDC92 | SNV | Missense_Mutation | novel | c.87C>A | p.Ser29Arg | p.S29R | Q53HC0 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-PE-A5DD-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | CR | |
| CCDC92 | SNV | Missense_Mutation | novel | c.739N>A | p.Leu247Met | p.L247M | Q53HC0 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| CCDC92 | SNV | Missense_Mutation | novel | c.778N>C | p.Glu260Gln | p.E260Q | Q53HC0 | protein_coding | tolerated(0.08) | possibly_damaging(0.892) | TCGA-C5-A3HF-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | PD |
| CCDC92 | SNV | Missense_Mutation | rs768819776 | c.490N>A | p.Ala164Thr | p.A164T | Q53HC0 | protein_coding | tolerated(0.09) | probably_damaging(0.989) | TCGA-5M-AAT6-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Unknown | Unknown | PD |
| CCDC92 | SNV | Missense_Mutation | novel | c.400N>A | p.Leu134Met | p.L134M | Q53HC0 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-A6-2672-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
| CCDC92 | SNV | Missense_Mutation | rs776087763 | c.892N>A | p.Ala298Thr | p.A298T | Q53HC0 | protein_coding | tolerated_low_confidence(0.09) | benign(0.001) | TCGA-A6-6653-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| CCDC92 | SNV | Missense_Mutation | rs777304210 | c.341C>T | p.Ala114Val | p.A114V | Q53HC0 | protein_coding | tolerated(0.05) | probably_damaging(0.997) | TCGA-AA-3947-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| CCDC92 | SNV | Missense_Mutation | c.880N>T | p.Arg294Trp | p.R294W | Q53HC0 | protein_coding | deleterious_low_confidence(0) | possibly_damaging(0.87) | TCGA-AA-3982-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |